CRO, Onyx Scientific, to Expand GMP Capability
![](/46/pdcnewsitem/03/43/31/TqVQd8pACxKvMVR.jpeg)
UK-based Onyx Scientific is to invest in growing its GMP space following an increase in demand for its small-scale API manufacturing services.
The move will see the installation of a new Class 100,000 suite at its facility in North East England aimed at satisfying an upsurge in Phase I/II GMP campaigns from clients in Europe and the US.
Onyx Scientific specialises in pre-clinical/clinical development projects and expansion plans were given the go ahead at the contract research organisation (CRO) following another successful audit by the MHRA in February.
Celebrating its 15th birthday this year, the CRO provides clients with the production of API up to 50l-100l under current GMP regulations, which dovetails its earlier stage custom synthesis, lead optimisation, solid state and analytical services.
Denise Bowser, commercial director at Onyx Scientific, said: “This latest investment will bring the total capacity at our UK site up to four dedicated GMP suites, which represents a steady but significant growth in this area over the past few years.
“We have worked with hundreds of clients at the small scale non-GMP stage and have been able to provide rapid scale up to GMP for many of them with the same technical team, all under one roof.
“So by having an additional GMP suite at our disposal, it gives us even greater flexibility to assist our clients that are under increasing timeline pressure to deliver against their development programmes.”
This latest venture by the chemistry specialist follows a significant investment into continuous flow manufacturing last year. This has allowed its clients to explore alternatives during product research and development programs, while overcoming the often time-consuming and costly process of batch manufacturing.
Onyx Scientific has achieved preferred partner status and undertaken GMP projects for some of the world’s largest pharmaceutical companies and major institutions such as Cancer Research UK.
The company also works with many specialty drug development firms and biotech organisations across the globe, helping accelerate candidates from discovery to production.
The CRO’s team has built a strong reputation for dealing with some of the most complex early stage chemistry challenges for companies developing new compounds.
The IPCA Laboratories-owned CRO assists companies with medicinal chemistry through Phase I-III. The UK site is then able to scale-up, tech transfer and increase efficiency using its parent company’s large scale API manufacturing sites in India.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance